Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: Characterization of a novel subset of CD4+/CD25+ T cells

Blood

Volumn 100, Issue 6, 2002, Pages 2159-2167

  Sereti, Irini ^a,b,c,d   Martinez Wilson, Hector ^a,b,c,d   Metcalf, Julia A ^a,b,c,d   Baseler, Michael W ^a,b,c,d   Hallahan, Claire W ^a,b,c,d   Hahn, Barbara ^a,b,c,d   Hengel, Richard L ^a,b,c,d   Davey, Richard T ^a,b,c,d   Kovacs, Joseph A ^a,b,c,d   Clifford Lane, H ^a,b,c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MITOGENIC AGENT;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 0037105607     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.6.2159.h81802002159_2159_2167     Document Type: Article

References (49)

1. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
2. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study
3. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
4. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
5. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
6. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
7. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
8. ILSTIM (ANRS 082). Interleukin 2 (IL2) accelerates CD4 cells reconstitution in patients with CD4 < 200/MM3 despite effective HAART
9. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
10. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with
11. AIDS CPfCRo. IL-2 therapy produces no change in HIV RNA after one year
12. 3: ACTG 328 results at 60 weeks
13. Expression of the IL-2 receptor γ subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component
14. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15
15. Sharing of a common γ chain, γ c, by the IL-2, IL-4, and IL-7 receptors: Implications for X-linked severe combined immunodeficiency (XSCID)
16. Biology of the interleukin-2 receptor
17. Cooperative interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits
18. The interleukin-2 receptor complex and signal transduction: Role of the β-chain
19. Circulating human T and B lymphocytes express the p55 interleukin-2 receptor molecule (TAC, CD25)
20. Interleukin 2 leads to dose-dependent expression of the α chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation
21. Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets
22. The interleukin-2 receptor subunit expression and function on peripheral blood lymphocytes from HIV-infected and control persons
23. Expression of IL-2 receptor sub-unit p55 (CD25) on normal human lymphocytes
24. Dysregulation of the interleukin-2 receptor α- and β-chain expression in CD4 and CD8 T cells in HIV infection
25. + subjects
26. high regulatory cells in human peripheral blood
27. T lymphocyte-mediated control of autoimmunity
28. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)
29. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
30. + T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms
31. + suppressor T cells
32. Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory T cells
33. Antigen-independent activation of naive and memory resting T cells by a cytokine combination
34. + T cells expressing IL-2 receptor α-chain (CD25) and having a functionally transitional nature into memory cells
35. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
36. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy
37. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients
38. + T cell turnover in HIV-infected patients
39. Cutting edge: Naive T cells masquerading as memory cells
40. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation
41. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selection on T cells during the virgin to memory cell transition
42. + T cell turnover rates
43. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV
44. + naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state
45. + immunoregulatory T cells is antigen nonspecific
46. + immunoregulatory cells
47. + T cells: A highly differentiated and apoptosis-prone population
48. + thymocytes and peripheral T cells have immune suppressive activity in vitro
49. + T cells with regulatory properties isolated from peripheral blood